PAVmed Statistics

Total Valuation

PAVmed has a market cap or net worth of $9.09 million. The enterprise value is $15.01 million.

Market Cap	9.09M
Enterprise Value	15.01M

Important Dates

The last earnings date was Thursday, November 13, 2025, before market open.

Earnings Date	Nov 13, 2025
Ex-Dividend Date	n/a

Share Statistics

PAVmed has 27.64 million shares outstanding. The number of shares has decreased by -52.96% in one year.

Current Share Class	27.64M
Shares Outstanding	27.64M
Shares Change (YoY)	-52.96%
Shares Change (QoQ)	+19.19%
Owned by Insiders (%)	9.54%
Owned by Institutions (%)	9.32%
Float	19.31M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	182.78
Forward PS	25.92
PB Ratio	0.90
P/TBV Ratio	1.08
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	517.52
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 0.40, with a Debt / Equity ratio of 0.36.

Current Ratio	0.40
Quick Ratio	0.32
Debt / Equity	0.36
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-877.83

Financial Efficiency

Return on equity (ROE) is 17.44% and return on invested capital (ROIC) is -41.64%.

Return on Equity (ROE)	17.44%
Return on Assets (ROA)	-36.78%
Return on Invested Capital (ROIC)	-41.64%
Return on Capital Employed (ROCE)	-73.13%
Revenue Per Employee	$744
Profits Per Employee	-$15,282
Employee Count	39
Asset Turnover	0.00
Inventory Turnover	0.71

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -70.09% in the last 52 weeks. The beta is 1.10, so PAVmed's price volatility has been similar to the market average.

Beta (5Y)	1.10
52-Week Price Change	-70.09%
50-Day Moving Average	0.41
200-Day Moving Average	0.56
Relative Strength Index (RSI)	42.77
Average Volume (20 Days)	484,118

Short Selling Information

The latest short interest is 481,091, so 1.74% of the outstanding shares have been sold short.

Short Interest	481,091
Short Previous Month	256,466
Short % of Shares Out	1.74%
Short % of Float	2.49%
Short Ratio (days to cover)	0.69

Income Statement

In the last 12 months, PAVmed had revenue of $29,000 and -$596,000 in losses. Loss per share was -$0.22.

Revenue	29,000
Gross Profit	-152,000
Operating Income	-20.19M
Pretax Income	1.43M
Net Income	-596,000
EBITDA	-20.03M
EBIT	-20.19M
Loss Per Share	-$0.22

Full Income Statement

Balance Sheet

The company has $3.37 million in cash and $9.28 million in debt, giving a net cash position of -$5.92 million or -$0.21 per share.

Cash & Cash Equivalents	3.37M
Total Debt	9.28M
Net Cash	-5.92M
Net Cash Per Share	-$0.21
Equity (Book Value)	25.79M
Book Value Per Share	0.37
Working Capital	-6.27M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$3.56 million and capital expenditures -$21,000, giving a free cash flow of -$3.58 million.

Operating Cash Flow	-3.56M
Capital Expenditures	-21,000
Free Cash Flow	-3.58M
FCF Per Share	-$0.13

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-69,620.69%
Pretax Margin	4,931.03%
Profit Margin	10,672.41%
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

PAVmed does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	52.96%
Shareholder Yield	52.96%
Earnings Yield	-6.55%
FCF Yield	-39.39%

Dividend Details

Analyst Forecast

The average price target for PAVmed is $20.00, which is 5,979.03% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$20.00
Price Target Difference	5,979.03%
Analyst Consensus	Strong Buy
Analyst Count	1
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

The last stock split was on December 7, 2023. It was a reverse split with a ratio of 1:15.

Last Split Date	Dec 7, 2023
Split Type	Reverse
Split Ratio	1:15

Scores

PAVmed has an Altman Z-Score of -10.91 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-10.91
Piotroski F-Score	1